This site is intended for US Healthcare Professionals

Sign Up for Updates
Sign Up for Updates
How to Prescribe

XDEMVY is simple and easy
for patients to use

1 drop per eye twice daily (~12 hours apart) for 6 weeks

No contraindications

If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart

Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted fifteen (15) minutes following its administration

See the faces and eyelids of patients with Demodex blepharitis (DB)

Craig, real patient with DB and cataracts

Craig,

real patient with DB and cataracts

  • 74-year-old photographer and professor
  • History of irritation, redness, and watery eyes before his diagnosis in 2022
  • Always aware of his eyes and concerned about DB's impact on his photography

I make my living with my eyes. If I could get a little relief or complete relief...I’m very excited.

Hear Craig’s story

Abby, real patient with DB

Abby,

real patient with DB

  • 52-year-old healthcare media professional diagnosed with DB in 2022
  • >5-year history of irritated eyelids
  • Deterred from wearing makeup and self-conscious in public because of how often she touches her eyes

I’ve been dealing with symptoms for 5 or 6 years...so the fact that I might be able to eradicate these mites with a simple drop treatment is huge.

Hear Abby’s story

Jared, real patient with DB and dry eye

Jared,

real patient with DB and dry eye

  • 28-year-old attorney
  • History of inflammation, eyelid redness, and crusties. Previously diagnosed with general blepharitis
  • Diagnosed with DB in 2023 during a consultation for LASIK

It was really exciting to hear that there was a treatment coming out for what I had because it really has impacted me.

Hear Jared’s story

See the faces and eyelids of patients with Demodex blepharitis (DB)

Craig, real patient with DB and cataracts

  • 74-year-old photographer and professor
  • History of irritation, redness, and watery eyes before his diagnosis in 2022
  • Always aware of his eyes and concerned about DB's impact on his photography

I make my living with my eyes. If I could get a little relief or complete relief...I’m very excited.

Hear Craig’s story

Abby, real patient with DB

  • 52-year-old healthcare media professional diagnosed with DB in 2022
  • >5-year history of irritated eyelids
  • Deterred from wearing makeup and self-conscious in public because of how often she touches her eyes

I’ve been dealing with symptoms for 5 or 6 years...so the fact that I might be able to eradicate these mites with a simple drop treatment is huge.

Hear Abby’s story

Jared, real patient with DB and dry eye

  • 28-year-old attorney
  • History of inflammation, eyelid redness, and crusties. Previously diagnosed with general blepharitis
  • Diagnosed with DB in 2023 during a consultation for LASIK

It was really exciting to hear that there was a treatment coming out for what I had because it really has impacted me.

Hear Jared’s story

Get the info you need to send Demodex mites packing

Sign Up for Updates

About XDEMVY

The first and only FDA-approved
treatment for Demodex blepharitis

How to Prescribe

Starting patients on XDEMVY is as easy as 1-2-3

Reference: XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023.

INDICATIONS AND USAGE
XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

IMPORTANT SAFETY INFORMATION:

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals, Inc. at 1-888-421-4002 or the FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see full Prescribing Information.

INDICATIONS AND USAGE
XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

IMPORTANT SAFETY INFORMATION:

WARNINGS AND PRECAUTIONS

Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.